​

Ocular Therapeutix Ownership | Who Owns Ocular Therapeutix?

OverviewForecastRevenueFinancialsChartTranscripts

Ocular Therapeutix Ownership Summary

Ocular Therapeutix is owned by 83.81% institutional investors, 1.06% insiders, and 15.13% retail investors. Summer road is the largest institutional shareholder, holding 11.28% of OCUL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.98% of its assets in Ocular Therapeutix shares.

OCUL Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockOcular Therapeutix83.81%1.06%15.13%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Summer road14.89M11.28%$101.82M
Vr adviser12.76M9.67%$87.30M
Deep track capital, lp12.72M9.64%$87.01M
Blackrock11.52M8.73%$78.80M
Vanguard group8.61M6.52%$58.91M
Avoro capital advisors8.06M6.11%$55.13M
Tcg crossover management5.32M4.03%$36.38M
Opaleye management5.31M4.02%$36.30M
Logos global management lp5.15M3.90%$35.23M
State street3.92M2.97%$26.82M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Summer road14.89M98.54%$101.82M
Acuta capital partners2.77M15.96%$18.95M
Opaleye management5.31M8.29%$36.30M
Vr adviser12.76M5.56%$87.30M
Rosalind advisors750.00K3.95%$5.13M
Tcg crossover management5.32M3.79%$36.38M
Deltec asset management2.59M3.39%$17.72M
Logos global management lp5.15M2.83%$35.23M
Octagon capital advisors lp2.42M2.61%$16.59M
Deep track capital, lp12.72M2.60%$87.01M

Top Buyers

HolderShares% AssetsChange
Blackrock11.52M0.00%3.46M
Adage capital partners gp3.70M0.05%3.32M
Point72 asset management2.71M0.05%2.71M
Braidwell lp1.64M0.35%1.64M
State street3.92M0.00%1.52M

Top Sellers

HolderShares% AssetsChange
Great point partners---1.73M
Opaleye management5.31M8.29%-1.35M
Franklin resources1.17M0.00%-998.15K
Nuveen asset management416.77K0.00%-796.67K
Invesco45.90K0.00%-726.47K

New Positions

HolderShares% AssetsChangeValue
Point72 asset management2.71M0.05%2.71M$18.51M
Braidwell lp1.64M0.35%1.64M$11.24M
Nantahala capital management1.00M0.40%1.00M$6.84M
Rosalind advisors750.00K3.95%750.00K$5.13M
Marshall wace, llp429.59K0.00%429.59K$2.94M

Sold Out

HolderChange
Financial gravity asset management-1.00
Nelson, van denburg & campbell wealth management group-17.00
Signaturefd-76.00
Ica group wealth management-220.00
Acadian asset management-2.54K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202417213.91%139,954,0592.07%830.78%79-13.19%4670.37%
Jun 30, 2024151-0.66%137,118,55510.64%1031.18%91-14.95%2717.39%
Mar 31, 202415224.59%123,928,59468.68%931.24%10769.84%23-23.33%
Dec 31, 20231223.39%73,470,45682.44%873.38%6316.67%303.45%
Sep 30, 2023118-16.90%40,270,842-7.02%501.65%54-22.86%29-23.68%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv4.64M2.98%7.62K
iShares Russell 2000 ETF4.02M2.58%-9.03K
Vanguard Institutional Extnd Mkt Idx Tr1.90M1.21%-14.75K
Fidelity Small Cap Index1.59M1.02%-40.67K
iShares Russell 2000 Growth ETF1.38M0.89%-
State St Russell Sm/Mid Cp® Indx NL Cl C959.07K0.62%-32.00K
Franklin Biotechnology Discv A(acc)USD759.90K0.49%-
Xtrackers S&P 500 Swap ETF 1C741.00K0.48%-
Fidelity Extended Market Index735.51K0.47%-198.54K
Vanguard Russell 2000 ETF709.30K0.45%-4.42K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 25, 2024Heier Jeffrey S. Chief Scientific OfficerSell$26.56K
Nov 25, 2024Kaiser Peter Chief Development OfficerSell$26.10K
Nov 25, 2024Nayak Sanjay Chief Strategy OfficerSell$16.33K
Nov 25, 2024Dugel Pravin See RemarksSell$186.33K
Aug 23, 2024Nayak Sanjay Chief Strategy OfficerSell$16.52K

Insider Transactions Trends

DateBuySell
2024 Q4-4
2024 Q3-2
2024 Q2-2
2024 Q1110
2023 Q41-

OCUL Ownership FAQ

Who Owns Ocular Therapeutix?

Ocular Therapeutix shareholders are primarily institutional investors at 83.81%, followed by 1.06% insiders and 15.13% retail investors. The average institutional ownership in Ocular Therapeutix's industry, Biotech Stocks , is 47.04%, which Ocular Therapeutix exceeds.

Who owns the most shares of Ocular Therapeutix?

Ocular Therapeutix’s largest shareholders are Summer road (14.89M shares, 11.28%), Vr adviser (12.76M shares, 9.67%), and Deep track capital, lp (12.72M shares, 9.64%). Together, they hold 30.58% of Ocular Therapeutix’s total shares outstanding.

Does Blackrock own Ocular Therapeutix?

Yes, BlackRock owns 8.73% of Ocular Therapeutix, totaling 11.52M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 78.8M$. In the last quarter, BlackRock increased its holdings by 3.46M shares, a 42.87% change.

Who is Ocular Therapeutix’s biggest shareholder by percentage of total assets invested?

Summer road is Ocular Therapeutix’s biggest shareholder by percentage of total assets invested, with 98.54% of its assets in 14.89M Ocular Therapeutix shares, valued at 101.82M$.

Who is the top mutual fund holder of Ocular Therapeutix shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Ocular Therapeutix shares, with 2.98% of its total shares outstanding invested in 4.64M Ocular Therapeutix shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools